Dyspnea Assessment in Hemodialysis Patients

CompletedOBSERVATIONAL
Enrollment

7

Participants

Timeline

Start Date

March 29, 2019

Primary Completion Date

February 25, 2020

Study Completion Date

February 25, 2020

Conditions
Dyspnea; UremicEnd Stage Renal DiseaseChronic Lung DiseaseChronic Heart DiseaseHemodialysis-Induced SymptomSodium Excess
Interventions
DIAGNOSTIC_TEST

Lung MRI

Proton Lung Magnetic Resonance Imaging

DIAGNOSTIC_TEST

Sodium MRI

Sodium Soft Tissue Magnetic Resonance Imaging

DIAGNOSTIC_TEST

Chest CT

High-resolution Quantitative Chest CT

DIAGNOSTIC_TEST

Echocardiography

Transthoracic 2D Speckle-Tracking Echocardiography

DIAGNOSTIC_TEST

Fractional Exhaled Nitric Oxide

Fractional Exhaled Nitric Oxide testing

DIAGNOSTIC_TEST

Pulmonary Function Tests

Spirometry and Plethysmography

DIAGNOSTIC_TEST

Blood Sampling

Blood testing for: standard-of-care, inflammatory biomarkers, uremic toxins

DIAGNOSTIC_TEST

Six-Minute Walk Test

Six-Minute Walk Test

DIAGNOSTIC_TEST

Dyspnea Questionnaires

Modified Medical Research Council; University of California, San Diego Shortness of Breath Questionnaire; Borg Scale

Trial Locations (1)

Unknown

London Health Sciences Centre, London

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT03773991 - Dyspnea Assessment in Hemodialysis Patients | Biotech Hunter | Biotech Hunter